Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIRAV S PATEL

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1881631539
CMS profile
175708
Location
LOS ALAMITOS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$144,161.10

269 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIRAV S PATEL

NPI 1881631539 · CMS profile ID 175708

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

LOS ALAMITOS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881631539?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIRAV S PATEL, NPI 1881631539, CMS profile ID 175708. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881631539?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NIRAV S PATEL, NPI 1881631539, CMS profile ID 175708. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881631539?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NIRAV S PATEL, NPI 1881631539, CMS profile ID 175708, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881631539?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

269 matching records · $144,161.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 269 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 269.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PORTOLA PHARMACEUTICALS, INC. $2,100.0006/25/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705271217 CMS
Allergan Inc. $4.4106/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670928747 CMS
Allergan Inc. $3.3606/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670928745 CMS
Novartis Pharmaceuticals Corporation $18.2606/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659893079 CMS
Novartis Pharmaceuticals Corporation $13.4906/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659893081 CMS
Novartis Pharmaceuticals Corporation $23.6006/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659893071 CMS
Biogen, Inc. $114.0106/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660649577 CMS
Lilly USA, LLC $4.1806/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658060107 CMS
Genentech USA, Inc. $23.9606/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681270173 CMS
PORTOLA PHARMACEUTICALS, INC. $1,059.3805/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260759 CMS
PORTOLA PHARMACEUTICALS, INC. $2,000.0005/30/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260765 CMS
PORTOLA PHARMACEUTICALS, INC. $33.3305/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260777 CMS
UCB, Inc. $38.9505/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688373505 CMS
Allergan Inc. $18.6105/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670928743 CMS
PORTOLA PHARMACEUTICALS, INC. $468.0005/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260737 CMS
PORTOLA PHARMACEUTICALS, INC. $2,000.0005/22/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260743 CMS
PORTOLA PHARMACEUTICALS, INC. $133.6605/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260749 CMS
PORTOLA PHARMACEUTICALS, INC. $308.3005/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259099 CMS
PORTOLA PHARMACEUTICALS, INC. $308.3005/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259147 CMS
PORTOLA PHARMACEUTICALS, INC. $28.1305/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259165 CMS
PORTOLA PHARMACEUTICALS, INC. $15.0805/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259189 CMS
PORTOLA PHARMACEUTICALS, INC. $28.1305/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260725 CMS
PORTOLA PHARMACEUTICALS, INC. $2,000.0005/21/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260731 CMS
PORTOLA PHARMACEUTICALS, INC. $36.1705/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705267529 CMS
PORTOLA PHARMACEUTICALS, INC. $2,000.0005/20/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260709 CMS
PORTOLA PHARMACEUTICALS, INC. $312.0005/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260721 CMS
PORTOLA PHARMACEUTICALS, INC. $121.4705/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260727 CMS
PORTOLA PHARMACEUTICALS, INC. $82.9605/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259107 CMS
PORTOLA PHARMACEUTICALS, INC. $2,000.0005/16/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259131 CMS
PORTOLA PHARMACEUTICALS, INC. $837.0405/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259155 CMS
PORTOLA PHARMACEUTICALS, INC. $77.5405/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260767 CMS
PORTOLA PHARMACEUTICALS, INC. $125.0005/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259179 CMS
PORTOLA PHARMACEUTICALS, INC. $31.3205/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259203 CMS
PORTOLA PHARMACEUTICALS, INC. $2,000.0005/15/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260693 CMS
PORTOLA PHARMACEUTICALS, INC. $2,000.0005/14/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259103 CMS
PORTOLA PHARMACEUTICALS, INC. $777.4105/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259151 CMS
PORTOLA PHARMACEUTICALS, INC. $74.3805/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259175 CMS
PORTOLA PHARMACEUTICALS, INC. $83.9505/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260701 CMS
PORTOLA PHARMACEUTICALS, INC. $40.6005/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259055 CMS
PORTOLA PHARMACEUTICALS, INC. $1,086.5005/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259079 CMS
PORTOLA PHARMACEUTICALS, INC. $123.6105/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705260713 CMS
PORTOLA PHARMACEUTICALS, INC. $2,000.0005/13/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705272131 CMS
PORTOLA PHARMACEUTICALS, INC. $64.7105/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259041 CMS
PORTOLA PHARMACEUTICALS, INC. $2,000.0005/09/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259065 CMS
PORTOLA PHARMACEUTICALS, INC. $482.6005/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259089 CMS
PORTOLA PHARMACEUTICALS, INC. $83.1205/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259137 CMS
PORTOLA PHARMACEUTICALS, INC. $1,000.0005/09/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259161 CMS
PORTOLA PHARMACEUTICALS, INC. $16.3805/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705272115 CMS
PORTOLA PHARMACEUTICALS, INC. $2,000.0005/07/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259047 CMS
PORTOLA PHARMACEUTICALS, INC. $521.6105/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705259071 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $144,161.10 269
PY2020 $85,645.38 191
PY2021 $121,111.52 237
PY2022 $124,134.26 248
PY2023 $139,710.25 256
PY2024 $109,608.10 212
PY2025 $30,578.91 143

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $327,308.24 44
PY2024 Principal investigator $78,125.10 25
PY2023 Recipient $29.90 1
PY2023 Principal investigator $50,075.52 16
PY2022 Principal investigator $97,105.89 26
PY2021 Recipient $1,556.10 1
PY2021 Principal investigator $254,094.47 40
PY2020 Principal investigator $163,282.86 34
PY2019 Principal investigator $163,810.84 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $500.00 12/31/2025 Non-covered Recipient Entity
COLLABORATIVE NUROSCIENCE RESEARCH
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202534651
Principal investigator 1 Janssen Research & Development, LLC $4,672.00 12/24/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175169863
Principal investigator 1 H. Lundbeck A S $365.00 12/19/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251778646
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 12/19/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175169881
Principal investigator 1 Janssen Research & Development, LLC $13,655.00 12/17/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175170125
Principal investigator 1 H. Lundbeck A S $1,220.00 12/11/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251778297
Principal investigator 1 ABBVIE INC. $3,600.00 12/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202528864
Principal investigator 1 Janssen Research & Development, LLC $1,563.00 11/21/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175169854
Principal investigator 1 H. Lundbeck A S $3,059.00 11/20/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251777505
Principal investigator 1 Janssen Research & Development, LLC $2,416.00 11/14/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175169903
Principal investigator 1 ABBVIE INC. $2,200.00 11/13/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202524133
Principal investigator 1 ABBVIE INC. $1,941.25 10/30/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202519747
Principal investigator 1 Janssen Research & Development, LLC $2,975.00 10/24/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175169928
Principal investigator 1 Janssen Research & Development, LLC $5,501.00 10/20/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175169998
Principal investigator 1 H. Lundbeck A S $3,767.00 10/16/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251775770
Principal investigator 1 Janssen Research & Development, LLC $5,718.00 09/25/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175170047
Principal investigator 1 Janssen Research & Development, LLC $26,295.00 09/19/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175170026
Principal investigator 1 H. Lundbeck A S $3,864.00 09/18/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251774848
Principal investigator 1 H. Lundbeck A S $7,880.00 08/26/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251773916
Principal investigator 1 Janssen Research & Development, LLC $4,378.00 08/20/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175170061
Principal investigator 1 Janssen Research & Development, LLC $1,567.00 08/08/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175169967
Principal investigator 1 ABBVIE INC. $8,058.75 08/06/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202502893
Principal investigator 1 Janssen Research & Development, LLC $8,250.00 07/28/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175170155
Principal investigator 1 ABBVIE INC. $1,837.50 07/02/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202494715
Principal investigator 1 Janssen Research & Development, LLC $63.00 07/02/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175169946
Principal investigator 1 ABBVIE INC. $500.00 06/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202492195
Principal investigator 1 Janssen Research & Development, LLC $20,351.00 06/13/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175172312
Principal investigator 1 ABBVIE INC. $5,970.00 05/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202483959
Principal investigator 1 Janssen Research & Development, LLC $7,179.00 04/18/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175173479
Principal investigator 1 ABBVIE INC. $500.00 04/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202476037
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 04/09/2025 Non-covered Recipient Entity
Memorialcare Hlth Syst
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175172802
Principal investigator 1 H. Lundbeck A S $1,000.00 04/01/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251769216
Principal investigator 1 Janssen Research & Development, LLC $1,236.00 03/19/2025 Non-covered Recipient Entity
Aetna - Memorialcare Hlth Syst Aco
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175169974
Principal investigator 1 ABBVIE INC. $2,985.00 03/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202461569
Principal investigator 1 H. Lundbeck A S $12,000.00 02/25/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251767673
Principal investigator 1 Janssen Research & Development, LLC $1,307.00 02/19/2025 Non-covered Recipient Entity
Aetna - Memorialcare Hlth Syst Aco
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175170018
Principal investigator 1 H. Lundbeck A S $14,528.00 02/05/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766991
Principal investigator 1 Novartis Pharmaceuticals Corporation $118,337.74 01/31/2025 Non-covered Recipient Entity
CENEXCEL CLINICAL RESEARCH
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190313185
Principal investigator 1 H. Lundbeck A S $9,750.00 01/29/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766724
Principal investigator 1 H. Lundbeck A S $2,000.00 01/29/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766727
Principal investigator 1 H. Lundbeck A S $9,000.00 01/29/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766736
Principal investigator 1 Janssen Research & Development, LLC $173.00 01/22/2025 Non-covered Recipient Entity
Aetna - Memorialcare Hlth Syst Aco
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175169871
Principal investigator 1 Janssen Research & Development, LLC $478.00 01/17/2025 Non-covered Recipient Entity
Aetna - Memorialcare Hlth Syst Aco
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175170104
Principal investigator 1 H. Lundbeck A S $1,168.00 01/07/2025 Non-covered Recipient Entity
NEVADA ADVANCED PAIN SPECIALISTS
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766248